Znowu Pani bezczelnie kłamie. Oto aktualne stanowisko EMEA na temat thimerosalu:

http://www.emea.europa.eu/pdfs/human/press/pus/119404en.pdf

Cytuję:

In March 2004. the C’PMP reviewed the latest evidence relating to the safety of thiomersal-containing vaccines. A number of well-designed population-based epidemiological studies documenting the safety profile of thiomersal are now available. These studies show no association between the vaccination with thiomersal-contaming vaccines and neurodevelopmental disorders such as speech disorders and autism. Furthermore, new data in infants indicate that ethylmercury is more rapidly excreted and therefore has substantially different pharmacokinetics than methylmercury. The new data suggest that ethylmercury may be less toxic than previously assumed, and therefore caution is needed in extrapolating the toxicity profile of methylmercury to ethylmercury.

Taking into account all the above, the CPMP concludes the following:

- The latest epidemiologic studies show no association between the vaccination with thiomersal-contaming vaccines and specific neurodevelopmental disorders.

- The CPMP re-emphasises that immunisation with vaccines containing thiomersal continues to offer outstanding benefits to the general population, including infants. The benefits of vaccination far outweigh the risks, if any, of exposure to thiomersal-containing vaccines.

- The CPMP acknowledges that, during some manufacturing processes, the use of organic mercury compounds is necessary and in such cases, residual levels might be present in the final product.

- In line with the global goal of reducing exposure to mercury, the development of vaccines without thiomersal or with the lowest possible levels of thiomersal and other mercury containing preservatives should continue to be promoted.

- When a preservative is required, as in multidose preparations, the use of thiomersal can be considered.

- Applications for vaccines containing thiomersal as a preservative will be evaluated on a case-by-case basis, taking into account in particular efficacy and public health needs.

- The presence of thiomersal (and other preservatives) in the composition of vaccines will be stated on the label and a warning regarding the risk of sensitisation in relation to thiomersal and other preservatives will be included in the Summary of Product Characteristics and Package Leaflet of such products.

Po raz kolejny wybiera Pani sobie tyle, ile pasuje do Pani z góry załozonej tezy!

Tymczaasem pod wpływem udokumentowanej ewidencji naukowej EMEA zmienila wcześniejsze stanowisko i dopuściła thiomerosal do użycia w krajach EU !!!